個人簡介
2003.09~2008.07 復旦大學生命科學學院/遺傳學研究所/遺傳工程國家重點實驗室 哲學博士
2008.10~2011.12 美國弗萊德.哈欽森癌症研究中心 基礎醫學研究部 博士後
2012.01~2017.07 美國弗萊德.哈欽森癌症研究中心 臨床醫學研究部 助理研究員
2017.08~2018.08 美國華盛頓大學醫學中心 訪問學者/教授
2018.09復旦大學生命科學學院/復旦大學人類表型組研究院 青年研究員/博士生導師
研究方向
精準醫學領域:免疫細胞治療,細胞工程設計及免疫細胞表型研究。
主要成果
1. Liu L& Riddell SR; Tagged chimeric effector molecules and receptors thereof. Publication number WO2015095895 A1; Application number PCT/US2014/072007
2. Liu L, Riddell SR & Hoffstrom BG Development of high-affinity Strep-tag II monoclonal antibodies for multiple functionalities and use with genetically modified cells. (Serial NO: 62/555,017/US Filing date: 9/6/2017)
3. Liu L, Riddell SR, Busch DH & Fräßle SP Development of chimeric receptors that are specific for strep-tag II and uses thereof (Serial NO: 62/555,012/US Filing date: 9/6/2017)
4. Liu L, Sommermeyer D, Cabanov A, Kosasih P, Hill T, Riddell SR Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy.Nature Biotechnology. 2016 Apr;34(4):430-4.F1000Prime»Article Recommendations
5. Liu L& Eisenman RN., Regulation of c-Myc Protein Abundance by a Protein Phosphatase 2A Glycogen Synthase Kinase 3 Negative Feedback Pathway,Genes & Cancer. 2012 Jan;3(1):23-36
6.Salter AI, Ivey RG, Kennedy JJ, Voillet V, Rajan A, Alderman EJ, Voytovich UJ, Lin C, Sommermeyer D,Liu L, Whiteaker JR, Gottardo R, Paulovich AG, Riddell SR Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Science Signaling. 2018 Aug 21;11(544)
7.Paszkiewicz PJ, Fräßle SP, Srivastava S, Sommermeyer D, Hudecek M, Drexler I, Sadelain M,Liu L, Jensen MC, Riddell SR, Busch DH. Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia.J Clin Invest. 2016 Nov 1; 126 (11):4262-4272.
8.Michael Hudecek‡, Daniel Sommermeyer‡, Paula L. Kosasih, Anne Silva,Lingfeng Liu, Christoph Rader, Michael C. Jensen, Stanley R. Riddell The non-signaling extracellular spacer domain of CD19- specific chimeric antigen receptors is decisive for in vivo antitumor activity.Cancer Immunol Res. 2015 Feb;3(2):125-35
9.Riddell SR, Sommermeyer D, Berger C,Liu Lingfeng, Balakrishnan A, Salter A, Hudecek M, Maloney DG, Turtle CJ, Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition.Cancer J. 2014 Mar-Apr; 20(2):141-4